MedWatch

Analyst: Obesity competition is good for Novo

According to analyst Søren Løntoft Hansen, Sydbank, it could turn out to be a positive development for Novo Nordisk and its Victoza business if US company Orexigen wins approval for its obesity drug.

Foto: Jens Dige/ JP

Last week’s announcement that US company Orexigen had submitted a registration application to the EMA for its obesity drug Contrave could turn out to be good news for Novo Nordisk and the Danish company’s own opportunities on the obesity market with diabetes drug Victoza – even if the Americans are the first to enter the market.

“It would be good for Novo if more companies were to enter the market, because it would probably increase the focus on this treatment option. Prescription drugs against obesity is a very uncultivated market, we know that much from the US market, so additional approvals, in both Europe and the US, will be a positive development for Novo Nordisk,” explains analyst Søren Løntoft Hansen, Sydbank.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier